Physical Activity and Ventricular Arrhythmias

Tachycardia, Ventricular Clinical Trial

Official title:

Physical Activity and Ventricular Arrhythmias

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04070300
• Other study ID #: 2018/1592
• Status: Completed
• Phase: N/A
• Start date: September 2, 2019
• Est. completion date: September 2, 2022

Study information

• Verified date: April 2023
• Source: St. Olavs Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of the study is to determine the effect of aerobic interval training in patients with an implantable cardioverter defibrillator (ICD) on physical fitness, quality of life and the amount of serious ventricular arrhythmic events on short and long term.

Description:

In this study, participants will be randomly assigned to either take part in the exercise program or serve as control and live as usual. At baseline study visit, study researchers will review medical records to collect various information, including the reason for needing an ICD, the type and settings of the ICD, medication use and medical history etc. All participants will undergo blood collection, complete a questionnaire to assess quality of life and undergo examination with echocardiography and ECG. The ICD will be programmed accordingly to international guidelines regarding ICD-therapy and optimal monitoring, before each participant complete an exercise treadmill test to determine VO2 peak. They will wear a Holter monitor to record heart activity 48 hours before the test and 24 hours after the test. All participants will then be observed for 2 months before being randomly assigned to either intervention or control. During this observation period, they will wear a fitness activity tracker wristband to evaluate degree of physical activity and a Holter monitor to register number of premature ventricular contractions. Participants taking part in the interval training group will perform aerobic interval training 4 x 4 minutes intervals, 3 times a week for 12 weeks (week 1-12), whereas participants taking part in the control group will carry on with usual daily life with no lifestyle recommendations. All participants will then undergo a new period of observation (week 13-20) and repeat the tests and examinations performed at baseline and during the observation period prior to intervention/control.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 55
• Est. completion date: September 2, 2022
• Est. primary completion date: September 2, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients with ICD and dilated cardiomyopathy or coronary heart disease as cause for implantation

• ICD implanted at St Olavs hospital, Trondheim

In case of difficulties with patient inclusion for the study, the criteria might be broadened to include patients with idiopathic ventricular arrhythmia as cause for implantation.

Exclusion Criteria:

• inability to accomplish the exercise program due to serious comorbidity or to participate in regular training within the next 3 months due to other reasons

• signs of severe cardiac ischemia or persistent ventricular tachycardia during individualized treadmill O2 peak test, which after individual assessment is to be found at risk

• comorbidity where endurance training at more than moderate intensity is discouraged

• severe cardiac valve disease

• planned surgery within the next 3 months

• inability to give informed consent

Related Conditions & MeSH terms

• Defibrillators, Implantable
• Tachycardia
• Tachycardia, Ventricular

Intervention

Behavioral:
• Interval exercise
Aerobic interval training during 12 weeks 3 times a week: 4 x 4 minutes intervals at an intensity of 90-95% of VO2 peak and active breaks of 3 minutes between intervals.

Locations

Country	Name	City	State
Norway	St Olavs Hospital	Trondheim

Sponsors (2)

Lead Sponsor	Collaborator
St. Olavs Hospital	Norwegian University of Science and Technology

Country where clinical trial is conducted

Norway, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in physical fitness/aerobic capacity	Expressed in and measured with maximal oxygen uptake (VO2 peak)	Change from baseline and after ended intervention period (12 weeks)
Primary	Change in assessment of quality of life	Patient-reported survey of patient health SF-36	Change from baseline and after intervention period (12 weeks)
Secondary	Change in burden of ventricular arrhythmias from baseline to week 9-12	Evaluated by number of ICD discharges (registered on ICD)	Baseline and the last 4 weeks of intervention period (week 9-12)
Secondary	Change in burden of ventricular arrhythmias from baseline to week 13-16	Evaluated by number of ICD discharges (registered on ICD)	Baseline and the first 4 weeks after intervention period (week 13-16)
Secondary	Change in burden of ventricular arrhythmias from baseline to week 9-16	Evaluated by number of ICD discharges (registered on ICD)	Baseline and the last 4 weeks of intervention period plus 4 first weeks after intervention period (week 9-16)
Secondary	Change in burden of ventricular arrhythmias from baseline to week 9-12	Evaluated by number of episodes with antitachycardia pacing (registered on ICD)	Baseline and the last 4 weeks of intervention period (week 9-12)
Secondary	Change in burden of ventricular arrhythmias from baseline to week 13-16	Evaluated by number of episodes with antitachycardia pacing (registered on ICD)	Baseline and the first 4 weeks after intervention period (week 13-16)
Secondary	Change in burden of ventricular arrhythmias from baseline to week 9-16	Evaluated by number of episodes with antitachycardia pacing (registered on ICD)	Baseline and the last 4 weeks of intervention period plus 4 first weeks after intervention period (week 9-16)
Secondary	Change in burden of ventricular arrhythmias from baseline to week 9-12	Evaluated by number of episodes with monitored ventricular tachycardias without ICD-therapy (registered on ICD)	Baseline and the last 4 weeks of intervention period (week 9-12)
Secondary	Change in burden of ventricular arrhythmias from baseline to week 13-16	Evaluated by number of episodes with monitored ventricular tachycardias without ICD-therapy (registered on ICD)	Baseline and the first 4 weeks after intervention period (week 13-16)
Secondary	Change in burden of ventricular arrhythmias from baseline to week 9-16	Evaluated by number of episodes with monitored ventricular tachycardias without ICD-therapy (registered on ICD)	Baseline and the last 4 weeks of intervention period plus 4 first weeks after intervention period (week 9-16)
Secondary	Change in burden of ventricular arrhythmias from baseline to week 9-12	Evaluated by number of premature ventricular contractions (registered on a 72 hours Holter monitoring)	Baseline and the last 4 weeks of intervention period (week 9-12)
Secondary	Change in burden of ventricular arrhythmias from baseline to week 13-16	Evaluated by number of premature ventricular contractions (registered on a 72 hours Holter monitoring)	Baseline and the first 4 weeks after intervention period (week 13-16)
Secondary	Change in burden of ventricular arrhythmias from baseline to week 9-16	Evaluated by number of premature ventricular contractions (registered on a 72 hours Holter monitoring)	Baseline and the last 4 weeks of intervention period plus 4 first weeks after intervention period (week 9-16)
Secondary	Cardiac function	Evaluated by changes in left ventricular dimensions and systolic/diastolic function assessed by echocardiography and blood values (NT-proBNP and troponin T)	Baseline and after ended intervention period (12 weeks)
Secondary	Change in degree of physical activity	Assessed by number of steps daily registered with fitness activity tracker wristband (worn for 1 week)	Baseline and after ended intervention period (12 weeks)
Secondary	Changes in adiposity	Evaluated by changes in waist circumference (cm) and BMI (kg/m^2) as measures of adiposity	Baseline and after ended intervention period (12 weeks)
Secondary	Changes in cholesterol value	Evaluated by changes in total cholesterol, HDL-cholesterol, LDL-cholesterol (all in mmol/L) as a measure of cardiac risk	Baseline and after ended intervention period (12 weeks)
Secondary	Changes in triglycerides value	Evaluated by changes in triglycerides ( in mmol/L) as a measure of cardiac risk	Baseline and after ended intervention period (12 weeks)
Secondary	Changes in heart rate variability	Evaluated by measuring changes in SDNN, SDANN 5, ASDNN 5 and RMSSD registered on a 72 hours Holter monitoring	Baseline and after ended intervention period (12 weeks)
Secondary	Changes in number of premature ventricular contractions during a single bout of high intensity exercise (VO2 peak test)	Measured by changes in the number of premature ventricular contractions during VO2 peak testing	Baseline and after ended intervention period (12 weeks)
Secondary	Changes in signal-averaged ECG (SA-ECG)	Measured by quantifying late potentials after depolarization of the ventricles	Baseline and after ended intervention period (12 weeks)